Enlivex Therapeutics announced that the first two patients have been dosed in the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. Einat Galamidi, MD., Vice President, Medical of Enlivex, stated “We are pleased with the enrollment and dosing of the first two patients in the open-label stage of the trial. This stage is designed to identify the dose and injection regimen for the randomized stage, and we look forward to the continued enrollment of additional patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Advances Osteoarthritis Trial in Denmark
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
- Enlivex announces DKMA authorization for Phase I/II trial of allocetra
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
- Enlivex’s Allocetra™ Shows Promise in Sepsis Trial